Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
Authors
Keywords
Anlotinib, Anti-angiogenesis, Phase I study, Advanced refractory solid tumors, Pharmacokinetics, Safety
Journal
Journal of Hematology & Oncology
Volume 9, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-10-04
DOI
10.1186/s13045-016-0332-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Aurora-B and HDAC synergistically regulate survival and proliferation of lymphoma cell via AKT, mTOR and Notch pathways
- (2016) Chong Wang et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma
- (2016) Camillo Porta et al. EUROPEAN UROLOGY
- Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma
- (2016) Chiara Ambrogio et al. NATURE MEDICINE
- Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo
- (2016) Susan Ashton et al. Science Translational Medicine
- Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: An up-to-date meta-analysis
- (2014) Wei-Xiang Qi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor
- (2013) F. J. Afonso et al. Clinical & Translational Oncology
- Expression of Proto-Oncogene cFMS Protein in Lung, Breast, and Ovarian Cancers
- (2013) Satoko Kakiuchi-Kiyota et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- FGFR2 gene amplification and clinicopathological features in gastric cancer
- (2012) K Matsumoto et al. BRITISH JOURNAL OF CANCER
- A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
- (2012) K. Mross et al. CLINICAL CANCER RESEARCH
- Development and strategies of VEGFR-2/KDR inhibitors
- (2012) Lingyi Huang et al. Future Medicinal Chemistry
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
- (2012) Niantao Deng et al. GUT
- Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings
- (2011) J. Beck et al. ANNALS OF ONCOLOGY
- Fibroblast growth factors and their receptors in cancer
- (2011) Jørgen Wesche et al. BIOCHEMICAL JOURNAL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
- (2010) Walter M. Stadler et al. CANCER
- FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
- (2010) N. Turner et al. CANCER RESEARCH
- Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
- (2009) Martin E Gore et al. LANCET ONCOLOGY
- De-regulated FGF receptors as therapeutic targets in cancer
- (2009) Victoria Knights et al. PHARMACOLOGY & THERAPEUTICS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started